Cadila Healthcare

From Wikipedia, the free encyclopedia

Not to be confused with Cadila Pharmaceuticals
Cadila Healthcare Limited
TypePublic
IndustryPharmaceuticals
Founded1952 (69 years ago) (1952)
FounderRamanbhai Patel
HeadquartersAhmedabad, Gujarat, India
Key people
Pankaj R. Patel, Chairman
Sharvil P. Patel, MD
Products
RevenueIncrease ₹15,139 crore (US$2.1 billion) (FY 2021)[1]
Increase ₹2,133 crore (US$300 million) (FY 2021)[1]
Number of employees
25,000 (2021)[1]
Websitewww.zyduscadila.com

Cadila Healthcare Limited (also known as Zydus Cadila) is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat, India primarily engaged in the manufacture of generic drugs.[2][3][4] It ranked 100th in the Fortune India 500 list in 2020.[5]

History[]

Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. It evolved over the next four decades into an established pharmaceutical company.

In 1995 the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals Ltd., and Cadila Healthcare Ltd became the Patel family's holding company. Cadila Healthcare had its initial public offering on the Bombay Stock Exchange in 2000 as stock code 532321.

In 2015 the company acquired another Indian pharmaceutical company called German Remedies. On 25 June 2007, the company acquired Química e Farmacêutica Nikkho do Brasil Ltda (Nikkho) as part of Zydus Healthcare Brasil Ltda.[6]

In 2010, Cadila Healthcare received a Wellcome Trust Award under the "R&D for Affordable Healthcare in India" initiative.

In 2014, Cadila Healthcare launched the world's first adalimumab biosimilar under the brand name Exemptia at one-fifth the originator's price.[7] Zydus Cadila Healthcare has also launched its first research based drug molecule Saroglitazar in treatment of Diabetic Dyslipidemia under brand name "Lipaglyn". SoviHep is the first sofosbuvir brand launched in India by Zydus in year 2015.[2]

In 2019, injectable ketorolac tromethamine manufactured by Zydus (Cadila Healthcare) was recalled due to microbial growth.

In 2020, Zydus Cadila's drug Desidustat received approval by the USFDA to initiate clinical trials on cancer patients.[8]

Products[]

From twenty five pharmaceutical production operations in India as well as a Zydus Cadila develops and manufactures a large range of pharmaceuticals as well as diagnostics, herbal products, skin care products and other OTC products. Starting from late 2015, having concluded a voluntary license agreement with Gilead, the company also produces the generics for hepatitis C treatment (i.e. sofosbuvir, distributed under the brand name SoviHep).[9]

The company makes active pharmaceutical ingredients at three sites in India, Ankleshwar plants, Vadodara plant, and Patalganga plant.

COVID-19 vaccine development[]

In July 2020, the company got permission to conduct human trials of the developmental COVID-19 vaccine named ZyCoV-D, from the Drugs Controller General of India (DCGI), Government of India.[10][11][12] It will be hitting the markets by September 2021.[13]

Cadila is also among the several Indian pharma companies that received the licensing agreements from the Gilead Sciences to produce remdesivir.[14]

Corporate control[]

Zydus Cadila's major shareholder remains the Patel family. Pankaj Patel (born 1953), son of the founder, is the chairman of the company. In 2004, Pankaj Patel was included in Forbes' annual list of India's richest people. As of 2020, Forbes estimates Patel's net worth at US $3.9 billion, making him India's 46th richest person.[15]

References[]

  1. ^ Jump up to: a b c "Audited Financial Results For The Year Ended March 31, 2021" (PDF). BSE. Retrieved 27 May 2021.
  2. ^ Jump up to: a b "Zydus launches SoviHep - the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences". The Hindu Business Line. 17 March 2015. Retrieved 29 December 2017.
  3. ^ "A Complete Overview on Cadila Healthcare, a growing and popular company in India". business.mapsofindia.com. 21 June 2011. Retrieved 4 February 2009.
  4. ^ "Cadila Healthcare Profit and Loss Reports - The Economic Times". economictimes.indiatimes.com. Retrieved 15 June 2020.
  5. ^ "Cadila Healthcare - Fortune 500 List 2020 - Fortune India". www.fortuneindia.com. Retrieved 12 January 2021.
  6. ^ Company Overview of Química e Farmacêutica Nikkho do Brasil Ltda Bloomberg
  7. ^ Zydus Cadila launches biosimilar of AbbVie's Humira in India The Economic Times 9 December 2014
  8. ^ Zydus Cadila Desidustat Gets USFDA Nod To Initiate Clinical Trials On Cancer Patients The Times Of India 23 July 2020
  9. ^ "Hepatitis C treatment in India for less than $1000". hep-c-news.com. Hep C News. 11 July 2016. Archived from the original on 16 September 2016.
  10. ^ "Potential COVID-19 vaccine by Zydus Cadila gets DCGI nod for human clinical trials". The Hindu. 3 July 2020.
  11. ^ "Zydus Cadila begins human clinical trials of COVID-19 vaccine candidate - ET HealthWorld". ETHealthworld.com.
  12. ^ "Zydus Cadila's COVID-19 Vaccine Candidate Found Safe in Early-Stage Human Trial". The New York Times. 5 August 2020.
  13. ^ "Cadila eyes nod for its vaccine by June". The Financial Express. 8 May 2021. Retrieved 24 May 2021.
  14. ^ Umarji, Vinay (12 June 2020). "Gilead finds fourth partner for manufacture of Remdesivir in Zydus Cadila". Business Standard India.
  15. ^ "Pankaj Patel". Forbes. Retrieved 15 June 2020.

External links[]

Retrieved from ""